Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
Alvotech and JAMP Pharma also announced the receipt of a marketing authorization in Canada for AVT04.
- Alvotech and JAMP Pharma also announced the receipt of a marketing authorization in Canada for AVT04.
- Product Revenue: Product revenue was $29.8 million for the nine months ended September 30, 2023, compared to $11.1 million for the same nine months of 2022.
- Income tax benefit: Income tax benefit was $67.1 million for the nine months ended September 30, 2023, compared to $14.8 million for the same nine months of 2022.
- Alvotech will conduct a business update conference call and live webcast on Wednesday, November 29 at 8:00 am ET (13:00 GMT).